Microplastics and Misinformation: What Science Really Says
November 12, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Depnon, Seridac, Tetradep
Synonyms :
mianserin
Class :
Antidepressants
Brand Name :
Depnon, Seridac, Tetradep
Synonyms :
mianserin
Class :
Antidepressants
Dosage Forms & StrengthsÂ
Tablet Â
10 mg Â
20 mgÂ
30 mg Â
Take an initial dose of 30 to 40 mg daily in divided doses or as a single dose at bedtime
Daily dose should not be more than 200 mg in divided doses
Not determined Â
Refer to adult dosingÂ
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
May increase the hypoglycemic effect of each other when combined
may have an increased antiplatelet effect when combined with nonsteroidal anti-inflammatory agents
meningococcal A C Y and W-135 diphtheria conjugate vaccine
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may have an increasingly adverse effect when combined with selective serotonin reuptake inhibitors
benzocaine: it may increase the risk or severity of CNS depression of mianserin
agomelatine: it may increase the risk of CNS depression of mianserin
alprazolam: it may decrease the risk of CNS depression of mianserin
may have an increasingly adverse effect when combined with selective serotonin reuptake inhibitors
mianserin: it may decrease the therapeutic effect of Alpha2-Agonists
mianserin: it may decrease the therapeutic effect of Alpha2-Agonists
mianserin: it may decrease the therapeutic effect of Alpha2-Agonists
mianserin: it may decrease the therapeutic effect of Alpha2-Agonists
mianserin: it may decrease the therapeutic effect of Alpha2-Agonists
CYP3A strong enhancers of the small intestine may reduce the bioavailability of mianserin 
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
it increases the toxicity of SSRIs
it increases the toxicity of SSRIs
it increases the effect of SSRIs
it increases the effect of SSRIs
SSRIs increase the antiplatelet effect of NSAIDs
SSRIs increase the antiplatelet effect of NSAIDs
SSRIs increase the antiplatelet effect of NSAIDs
SSRIs increase the antiplatelet effect of NSAIDs
SSRIs increase the antiplatelet effect of NSAIDs
may increase the serotonergic effect of Monoamine Oxidase Inhibitors
may have an increased serotonergic effect when combined with selective serotonin reuptake inhibitors
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may enhance the hypoglycemic effect of Agents with blood Glucose lowering effects
may enhance the hypoglycemic effect of Agents with blood Glucose lowering effects
may enhance the hypoglycemic effect of Agents with blood Glucose lowering effects
it decreases the efficacy of antiseizure agents
it decreases the efficacy of antiseizure agents
it decreases the efficacy of antiseizure agents
it decreases the efficacy of antiseizure agents
it decreases the efficacy of antiseizure agents
may enhance the antiplatelet effect of NSAIDs
may enhance the antiplatelet effect of NSAIDs
may enhance the antiplatelet effect of NSAIDs
may enhance the antiplatelet effect of NSAIDs
may enhance the antiplatelet effect of NSAIDs
may enhance the anti-cholinergic effect
may enhance the anti-cholinergic effect
may enhance the anti-cholinergic effect
may enhance the anti-cholinergic effect
may enhance the anti-cholinergic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
it increases the toxicity of anticholinergic agents
it increases the toxicity of anticholinergic agents
it increases the toxicity of anticholinergic agents
it increases the toxicity of anticholinergic agents
it increases the toxicity of anticholinergic agents
mianserin: they may diminish the serum concentration of CYP3A4 Inducers
mianserin: they may diminish the serum concentration of CYP3A4 Inducers
mianserin: they may diminish the serum concentration of CYP3A4 Inducers
mianserin: they may diminish the serum concentration of CYP3A4 Inducers
mianserin: they may diminish the serum concentration of CYP3A4 Inducers
mianserin: they may increase the CNS depressant effect of CNS Depressants
mianserin: they may increase the CNS depressant effect of CNS Depressants
mianserin: they may increase the CNS depressant effect of CNS Depressants
mianserin: they may increase the CNS depressant effect of CNS Depressants
mianserin: they may increase the CNS depressant effect of CNS Depressants
mianserin: they may decrease the therapeutic effect of antipsychotics
mianserin: they may decrease the therapeutic effect of antipsychotics
mianserin: they may decrease the therapeutic effect of antipsychotics
mianserin: they may decrease the therapeutic effect of antipsychotics
mianserin: they may decrease the therapeutic effect of antipsychotics
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
mianserin: they may enhance the serum concentration of CYP3A4 Inhibitors
mianserin: they may enhance the serum concentration of CYP3A4 Inhibitors
mianserin: they may enhance the serum concentration of CYP3A4 Inhibitors
mianserin: they may enhance the serum concentration of CYP3A4 Inhibitors
mianserin: they may enhance the serum concentration of CYP3A4 Inhibitors
mianserin: it may increase the risk or severity of CNS depression
mianserin: it may increase the risk or severity of CNS depression
mianserin: it may increase the risk or severity of CNS depression
may decrease the therapeutic effect when combined with Alpha2-Agonists
may decrease the therapeutic effect when combined with Alpha2-Agonists
may decrease the therapeutic effect when combined with Alpha2-Agonists
may decrease the therapeutic effect when combined with Alpha2-Agonists
may decrease the therapeutic effect when combined with Alpha2-Agonists
it increases the anticholinergic agents
Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K
Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K
Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K
Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K
Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K
may increase the anti-cholinergic effect
may increase the antiplatelet effect
may increase the anticholinergic effect of anticholinergic agents
may increase the hyponatremic effect of thiazide and thiazide-like diuretics
may increase the hypoglycemic effect of blood glucose-lowering agents
may increase the toxic effect of antipsychotic agents
may enhance the effect of SSRI
may enhance the effect of SSRI
may enhance the effect of SSRI
may enhance the effect of SSRI
may enhance the effect of SSRI
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
empagliflozin and linagliptinÂ
may increase the hypoglycaemic effect when combined
may increase the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may increase the Glucose-lowering effect of Agents with Blood Glucose Lowering Effects
SSRIs increase the CNS depressing effect of brexanolone
Actions and SpectrumÂ
mianserin blocks certain subtypes of serotonin receptors like the 5-HT2A and 5-HT2C receptors.  Â
mianserin can increase the availability of serotonin in certain brain regions, potentially leading to an antidepressant effect. Â
mianserin blocks alpha-2 adrenergic receptors, which are normally responsible for inhibiting the release of norepinephrine.
Frequency not defined Â
Orthostatic hypotension Â
QT prolongationÂ
Suicidal behaviorÂ
RashÂ
SweatingÂ
Bone fractureÂ
LeucopeniaÂ
Aplastic anemiaÂ
Hepatic disorder Â
Ventricular arrhythmias Â
AgranulocytosisÂ
JaundiceÂ
Arthralgia Â
Headache Â
TremorÂ
Seizure Â
Withdrawal symptomsÂ
ArthritisÂ
Dizziness Â
Breast disorder
Black Box WarningÂ
NoneÂ
Contraindication/Caution:Â
Contraindication:Â
Caution:Â
Pregnancy consideration:Â
Pregnancy category: N/AÂ
Lactation: Excretion into human milk is unknown Â
Pregnancy Categories:        Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women. Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.Â
Category N: There is no data available for the drug under this category.Â
Pharmacology Â
mianserin has antagonistic effects on alpha-1 adrenergic receptors. This action can contribute to orthostatic hypotension, a drop in blood pressure upon standing, which is a potential side effect of the medication. mianserin has a weaker antagonistic effect on dopamine receptors. Â
PharmacodynamicsÂ
mianserin’s antagonistic effects on alpha-1 adrenergic receptors can cause dilation of blood vessels and decrease blood pressure. Â
mianserin has anticholinergic effects due to its interaction with muscarinic acetylcholine receptors.Â
PharmacokineticsÂ
Absorption  Â
mianserin is absorbed from the gastrointestinal tract after oral administration. Â
DistributionÂ
mianserin is distributed throughout the body after absorption. Â
MetabolismÂ
mianserin undergoes extensive metabolism in the liver. Â
Elimination and excretionÂ
mianserin and its metabolites are excreted primarily in the urine.
AdministrationÂ
mianserin is administered orally in the form of tablets.
Patient information leafletÂ
Generic Name: mianserinÂ
Why do we use mianserin?Â
mianserin is used for the treatment of major depressive disorder, it is a serious mood disorder characterized by persistent feelings of sadness, or loss of interest. mianserin is also used in cases of treatment-resistant depressionÂ
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
